Historical Evolution of Second-Line Therapy in Non-Small Cell Lung Cancer

Innovative therapeutic agents have significantly improved outcome with an acceptable safety profile in a substantial proportion of non-small cell lung cancer (NSCLC) patients, who depend on oncogenic molecular alterations for their malignant phenotype. Despite the survival improvement achieved with...

Descripción completa

Detalles Bibliográficos
Autores principales: Lazzari, Chiara, Bulotta, Alessandra, Ducceschi, Monika, Viganò, Maria Grazia, Brioschi, Elena, Corti, Francesca, Gianni, Luca, Gregorc, Vanesa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5253463/
https://www.ncbi.nlm.nih.gov/pubmed/28168189
http://dx.doi.org/10.3389/fmed.2017.00004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5253463/
https://www.ncbi.nlm.nih.gov/pubmed/28168189
http://dx.doi.org/10.3389/fmed.2017.00004

Ejemplares similares